特発性肺線維症(Idiopathic Pulmonary Fibrosis):治療薬開発パイプライン動向(2015年上半期版)...市場調査レポートについてご紹介

【英文タイトル】Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Idiopathic Pulmonary Fibrosis Overview 9
Therapeutics Development 10
Pipeline Products for Idiopathic Pulmonary Fibrosis – Overview 10
Pipeline Products for Idiopathic Pulmonary Fibrosis – Comparative Analysis 11
Idiopathic Pulmonary Fibrosis – Therapeutics under Development by Companies 12
Idiopathic Pulmonary Fibrosis – Therapeutics under Investigation by Universities/Institutes 17
Idiopathic Pulmonary Fibrosis – Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Idiopathic Pulmonary Fibrosis – Products under Development by Companies 21
Idiopathic Pulmonary Fibrosis – Products under Investigation by Universities/Institutes 25
Idiopathic Pulmonary Fibrosis – Companies Involved in Therapeutics Development 26
AdAlta Pty Ltd. 26
Aeolus Pharmaceuticals, Inc. 27
AnaptysBio, Inc. 28
Auspex Pharmaceuticals, Inc. 29
Biogen Idec Inc. 30
Bioneer Corporation 31
BiOrion Technologies B.V. 32
Boehringer Ingelheim GmbH 33
Bristol-Myers Squibb Company 34
Carolus Therapeutics, Inc. 35
Celgene Corporation 36
Chong Kun Dang Pharmaceutical Corp. 37
Compugen Ltd. 38
F. Hoffmann-La Roche Ltd. 39
FibroGen, Inc. 40
Five Prime Therapeutics, Inc. 41
GenKyoTex S.A. 42
Gilead Sciences, Inc. 43
GlaxoSmithKline plc 44
HanAll Biopharma Co., Ltd. 45
Histocell S.L. 46
iBio, Inc. 47
ImmuneWorks, LLC 48
Inventiva SAS 49
Kadmon Corporation, LLC 50
Kasiak Research Pvt. Ltd. 51
Kyorin Pharmaceutical Co., Ltd. 52
Lanthio Pharma B.V. 53
LTT Bio-Pharma Co., Ltd. 54
MedImmune, LLC 55
Moerae Matrix, Inc. 56
MSM Protein Technologies, Inc. 57
Pacific Therapeutics Ltd. 58
Pharmaxis Limited 59
Progenra, Inc. 60
Promedior, Inc. 61
ProMetic Life Sciences Inc. 62
Pulmatrix, Inc. 63
Sanofi 64
Therametrics holding AG 65
Idiopathic Pulmonary Fibrosis – Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Combination Products 67
Assessment by Target 68
Assessment by Mechanism of Action 71
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 77
(pentoxifylline + acetylcysteine) – Drug Profile 77
AEOL-10150 – Drug Profile 78
AM-0010 – Drug Profile 81
Antibodies to Inhibit LPA1 for Idiopathic Pulmonary Fibrosis – Drug Profile 82
Antisense RNAi Oligonucleotide for COPD and IPF – Drug Profile 83
BMS-986020 – Drug Profile 84
BOT-191 – Drug Profile 85
CC-539 – Drug Profile 86
CC-90001 – Drug Profile 87
CGEN-25009 – Drug Profile 88
CKD-942 – Drug Profile 89
CT-2009 – Drug Profile 90
FG-3019 – Drug Profile 91
FPA-008 – Drug Profile 93
GKT-137831 – Drug Profile 94
GKT-901 – Drug Profile 95
HC-016 – Drug Profile 96
HL-156FIB – Drug Profile 97
HR-017 – Drug Profile 98
IBIOCFB-03 – Drug Profile 99
ICG-001 – Drug Profile 100
interferon gamma-1b – Drug Profile 101
IVA-337 – Drug Profile 102
IW-001 – Drug Profile 103
KBP-7018 – Drug Profile 104
KD-025 – Drug Profile 105
lebrikizumab – Drug Profile 107
LP2 – Drug Profile 109
LT-0011 – Drug Profile 110
LTI-03 – Drug Profile 111
MMI-0100 – Drug Profile 112
Monoclonal Antibody for Idiopathic Pulmonary Fibrosis – Drug Profile 113
MSM-735 – Drug Profile 114
NAS-911 – Drug Profile 115
nintedanib – Drug Profile 117
omipalisib – Drug Profile 121
PBF-1250 – Drug Profile 122
PBI-4050 – Drug Profile 123
pirfenidone – Drug Profile 124
PRM-151 – Drug Profile 125
PUR-1500 – Drug Profile 127
PXS-25 – Drug Profile 128
PXS-4820 – Drug Profile 129
PXS-64 – Drug Profile 130
Refacell-IPF – Drug Profile 131
RNAi Oligonucleotides for Idiopathic Pulmonary Fibrosis – Drug Profile 132
SAR-156597 – Drug Profile 133
SD-560 – Drug Profile 134
simtuzumab – Drug Profile 135
Small Molecule 2 for Chronic Respiratory Diseases – Drug Profile 137
Small Molecules to Antagonize Integrin Alpha V for Idiopathic Pulmonary Fibrosis – Drug Profile 138
Small Molecules to Inhibit LOXL2 for Oncology and Fibrosis – Drug Profile 139
Small Molecules to Inhibit USP34 for Idiopathic Pulmonary Fibrosis – Drug Profile 140
SPL-334 – Drug Profile 141
Stem Cell Therapy for Idiopathic Lung Fibrosis – Drug Profile 142
Stem Cell Therapy for Lung Fibrosis – Drug Profile 143
STX-100 – Drug Profile 144
TD-139 – Drug Profile 145
tipelukast – Drug Profile 146
tralokinumab – Drug Profile 148
vismodegib – Drug Profile 150
ZL-2102 – Drug Profile 153
Idiopathic Pulmonary Fibrosis – Recent Pipeline Updates 154
Idiopathic Pulmonary Fibrosis – Dormant Projects 193
Idiopathic Pulmonary Fibrosis – Discontinued Products 194
Idiopathic Pulmonary Fibrosis – Product Development Milestones 195
Featured News & Press Releases 195
Appendix 203
Methodology 203
Coverage 203
Secondary Research 203
Primary Research 203
Expert Panel Validation 203
Contact Us 203
Disclaimer 204


【レポート販売概要】

■ タイトル:特発性肺線維症(Idiopathic Pulmonary Fibrosis):治療薬開発パイプライン動向(2015年上半期版)
■ 英文:Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015
■ 発行日:2015年3月26日
■ 調査会社:Global Markets Direct
■ 商品コード:GMDHC6473IDB
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。